» Articles » PMID: 34502312

Links Between Infections, Lung Cancer, and the Immune System

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Sep 10
PMID 34502312
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is the leading disease of cancer-related deaths worldwide. Since the beginning of the 20th century, various infectious agents associated with lung cancer have been identified. The mechanisms that include systemic inflammatory pathways as effect of microbial persistence in the lung can secondarily promote the development of lung carcinogenesis. Chronic inflammation associated with lung-cancer infections is known to precede tumor development, and it has a strong effect on the response(s) to therapy. In fact, both viral and bacterial infections can activate inflammatory cells and inflammatory signaling pathways. In this review, an overview of critical findings of recent studies investigating associations between each of viral and bacterial pathogens and lung carcinoma is provided, with particular emphasis on how infectious organisms can interfere with oncogenic processes and all the way through immunity. Moreover, a discussion of the direct crosstalk between lung tumor development and inflammatory processes is also presented.

Citing Articles

Evaluating the Risks of Heated Tobacco Products: Toxicological Effects on Two Selected Respiratory Bacteria and Human Lung Cells.

Furnari S, Emma R, Caruso M, Furneri P, Fuochi V Toxics. 2025; 13(2).

PMID: 39997888 PMC: 11860425. DOI: 10.3390/toxics13020070.


Microbes, macrophages, and melanin: a unifying theory of disease as exemplified by cancer.

Berg S, Berg J Front Immunol. 2025; 15:1493978.

PMID: 39981299 PMC: 11840190. DOI: 10.3389/fimmu.2024.1493978.


Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy.

Wang X, Wu Y, Hu W, Zhang J BMC Cancer. 2025; 25(1):307.

PMID: 39979857 PMC: 11843754. DOI: 10.1186/s12885-025-13743-7.


Dose-dependent M2 macrophage polarization induced by Talaromyces marneffei promotes lung cancer cell growth via arginine-ornithine-cycle activation.

Chen A, Yu Q, Zheng L, Yi J, Tang Z, Ge H Med Microbiol Immunol. 2025; 214(1):11.

PMID: 39948184 DOI: 10.1007/s00430-025-00819-1.


Redox-Modulating Capacity and Effect of Ethyl Acetate Roots and Aerial Parts Extracts from L. on the Phenotype Inhibition of the Las/RhI Quorum Sensing System.

Dimitrova L, Mileva M, Georgieva A, Tzvetanova E, Popova M, Bankova V Plants (Basel). 2025; 14(2).

PMID: 39861566 PMC: 11768107. DOI: 10.3390/plants14020213.


References
1.
Bearz A, Vaccher E, Talamini R, Berretta M, Tirelli U . Comment on 'Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection'. Br J Cancer. 2012; 106(11):1899-900. PMC: 3364116. DOI: 10.1038/bjc.2012.181. View

2.
Luo Y, Wu C, Wu W, Huang C, Su W, Tsai C . Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. J Thorac Oncol. 2011; 7(2):299-305. DOI: 10.1097/JTO.0b013e31823c588d. View

3.
Bosteels C, Neyt K, Vanheerswynghels M, van Helden M, Sichien D, Debeuf N . Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection. Immunity. 2020; 52(6):1039-1056.e9. PMC: 7207120. DOI: 10.1016/j.immuni.2020.04.005. View

4.
Langan E, Graetz V, Allerheiligen J, Zillikens D, Rupp J, Terheyden P . Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. Lancet Oncol. 2020; 21(1):e55-e65. DOI: 10.1016/S1470-2045(19)30674-6. View

5.
Fujita K, Terashima T, Mio T . Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. J Thorac Oncol. 2016; 11(12):2238-2240. DOI: 10.1016/j.jtho.2016.07.006. View